NextCure, Inc.

NASDAQ: NXTC · Healthcare · Biotechnology

PublicHQ Beltsville, MD · Prince George'sCIK 0001661059Reports USD

#536 of 1,422 Healthcare companies by revenuetop-decile growth

EA Score

38D

FH 32DQ 45GM —SS 45

v0.1 · 55/100 weight · provisional

↑ revenue growth (YoY), filing timeliness · ↓ Piotroski F, disclosure history

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$55.8M

Employees

as of 2026-08-23

Market cap

$22.7M

as of 2026-08-23

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$22.4M$22.4M2020

Net income-$55.8M-$55.8M2025

Operating income-$57.6M-$57.6M2025

Total assets$50.2M$50.2M2025

Liabilities$15.2M$15.2M2025

Equity$34.9M$34.9M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is NextCure, Inc.’s revenue?

NextCure, Inc. booked $22.4M in FY2020 revenue, growing 253% year over year — faster than 90% of Healthcare companies we track, at a -249.5% net margin.

Peers · Healthcare

Covalon Technologies Ltd.78B+Wellgistics Health, Inc.19D Body and Mind Inc.——DarioHealth Corp.49D Ayurcann Holdings Corp.57C Item 9 Labs Corp.——

Neighbors

Prince George's →

IonQ, Inc.$130.0M53D Landmark Land Company, Inc.$12.2M——

Key facts

CEOMichael S. Richman

SectorHealthcare

IndustryBiotechnology

HeadquartersBeltsville, MD

ExchangeNASDAQ: NXTC

Employees40

IPO date2019-05-09

Latest filings

10-Q2026-08-06 8-K2026-08-06 8-K2026-07-14 8-K2026-06-25 8-K2026-06-01 8-K2026-05-07 10-Q2026-05-07 DEF 14A2026-04-24

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.